Medical/Pharmaceuticals
Meihua International Medical Technologies Co., Ltd. to Present at the Sidoti Small Cap Conference and Update Investors at the Emerging Growth Conference on June 13, 2024
YANGZHOU, China, June 11, 2024 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (Nasdaq: MHUA), a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries inChina, is pleased to announce that it...
2024-06-11 18:00
3859
Biosion Today Presented Key Phase 2 POC Clinical Study Results for Bosakitug, an Anti-TSLP mAb, in Atopic Dermatitis Subjects at the Revolutionizing Atopic Dermatitis Conference
NEWARK, Del. and NANJING, China, June 11, 2024 /PRNewswire/ -- Biosion, a global, clinical-stage biotechnology company,today presented key results from the ADAMANT study, a phase 2 proof-of-concept trial in AD subjects treated with Bosakitug, a high potency anti-TSLP mAb, in a podium presentation...
2024-06-11 18:00
4602
111, Inc., Scrianen Announce Strategic Direct Supply Partnership to Expand Nationwide Reach and Improve Drug Accessibility
SHANGHAI, June 11, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream inChina, announced that the Company has ent...
2024-06-11 15:57
4461
ITC final initial determination Ruled in favor of Hugel (no violation of Section 337)
SEOUL, South Korea, June 10, 2024 /PRNewswire/ -- Hugel Inc, a global total medical aesthetics company, announced that the Administrative Law Judge (ALJ) for its U.S. International Trade Commission(ITC) investigation issued an initial determination onJune 10th (local time) finding that "there is ...
2024-06-11 11:33
3205
Gannex Announces Poster Presentation of Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy-Confirmed MASH at EASL CONGRESS 2024
--Up to 68.2% mean relative reduction in liver fat content from baseline among biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients receiving 12-week treatment of ASC41 --Significant and clinically meaningful reductions in liver fat, alanine aminotransferase(ALT), as...
2024-06-11 08:10
3178
Full-Life Technologies Disclosed Preclinical Data of its NTSR1-targeting RDC Program FL-091 in an Oral Presentation at the 2024 SNMMI Annual Meeting
SHANGHAI and HEIDELBERG, Germany, June 10, 2024 /PRNewswire/ -- Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, released preclinical data of its NTSR1-targeting RDC program FL-091 in an oral presentation at the 2024 SNMMI (The Society of Nuclear Medicine a...
2024-06-11 08:00
2896
Smartee Successfully Hosts GS Mandibular Repositioning Conference in Spain
MADRID, June 10, 2024 /PRNewswire/ -- The Smartee GS Mandibular Repositioning Technology Conference was successfully held inMadrid, Spain. This gathering provided a unique space for international dental professionals to engage in in-depth dialogue and exchange ideas on Smartee's innovative S8 ort...
2024-06-10 21:19
2255
Kangpu Biopharmaceuticals to Present Results from Phase 2a of KPG-818 in SLE at EULAR 2024
HEFEI, China, June 10, 2024 /PRNewswire/ -- Kangpu Biopharmaceuticals today announced that a poster tour presentation highlighting the Phase 2a clinical data of KPG-818 in patients with Systemic Lupus Erythematosus (SLE) will be presented at the upcoming Annual European Congress of Rheumatology E...
2024-06-10 20:00
3047
FDA Grants Fast Track Designation to GCBP and Novel Pharma's GC1130A
* FDA's Fast Track designation speeds up the development of new biologic drugs for rare diseases YONGIN, South Korea, June 10, 2024 /PRNewswire/ -- GC Biopharma (006280. KS) and Novel Pharma have announced that the U.S. FDA has granted Fast Track Designation for their jointly developed MPSIIIA ...
2024-06-10 16:18
3550
J INTS BIO, ASCO 2024 - JIN-A02 showed tumor reductions including brain metastasis in the ongoing first-in-human, dose-finding Phase 1 clinical study
SEOUL, South Korea, June 10, 2024 /PRNewswire/ -- J INTS BIO provided an update of its ongoing Phase 1 clinical study of JIN-A02, a 4th generation EGFR-TKI for NSCLC treatment, during the 3rd of June poster session of the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting held at Mc...
2024-06-10 13:56
2468
DeepQure receives IDE Approval from FDA for its EFS study to treat Resistant Hypertension with its Extravascular Renal Denervation Technology (HyperQure™)
SEOUL, South Korea, June 10, 2024 /PRNewswire/ -- DeepQure, a Seoul based medical device company with a novel, extravascular (laparoscopic approach) solution for renal denervation (RDN), today announced initiation of its Early Feasibility Study (EFS) for the HyperQure™ system following FDA IDE ap...
2024-06-10 13:14
3653
United Imaging Prepares to Ship its 30,000th Unit Globally, a uMI Panorama GS, from Houston for U.S. Installation
The uMI Panorama GS is among the all-digital Molecular Imaging systems United Imaging is featuring at SNMMI in Toronto SHANGHAI, June 8, 2024 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, is on the brink of a significant milestone as it a...
2024-06-08 21:00
5351
Qilu Pharmaceutical's Three Clinical Studies on Cancer Immunotherapy Presented at ASCO 2024
JINAN, China, June 6, 2024 /PRNewswire/ -- The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting convened fromMay 31 to June 4, 2024 in Chicago, USA, adopting a hybrid format. Among the presented works, three clinical studies from Qilu Pharmaceutical were selected for poster sessio...
2024-06-07 14:51
2833
MicuRx: Successful Completion of Phase I Clinical Trial for Self-Developed MRX-8 Antibacterial Drug in China
* According to the World Health Organization (WHO), millions of patients face treatment difficulties or even life-threatening conditions due to resistant bacterial infections each year. * MRX-8 not only shows excellent safety and tolerability but also demonstrates strong antibacterial activit...
2024-06-06 19:52
2916
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer
ROCKVILLE, Md., June 6, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of...
2024-06-06 19:00
2662
ECHO IQ TECHNOLOGY CHAMPIONED IN INDEPENDENT SCIENTIFIC REVIEW
Echo IQ's EchoSolv-AS decision-support software for cardiology delivers significant potential benefits to hospital networks according to independent scientific presentation at prestigious New York Valves scientific conference. NEW YORK, June 6, 2024 /PRNewswire/ -- At the Structural Heart Summit ...
2024-06-06 13:14
3029
STRENGTHENING PATIENT CARE AND SAFETY IN COMPLEX, HIGH-RISK PAEDIATRIC LIVER TRANSPLANT SURGERY
Innovative mixed reality technology enhances pre-surgical planning at NUH's specialised paediatric organ transplant centre inSingapore SINGAPORE, June 5, 2024 /PRNewswire/ -- For the last three decades, the transplant team at theNational University Hospital (NUH)'s Department of Paediatric Surg...
2024-06-05 22:00
3509
Pricing plan from Done aims to make diagnosis and treatment of ADHD more accessible and affordable
SAN FRANCISCO, June 5, 2024 /PRNewswire/ -- Healthcare can be a significant financial burden on many individuals and families, even with insurance. The costs associated with one of the more common health issues in the US, the diagnosis and treatment of adult ADHD, can spill over into many aspects...
2024-06-05 22:00
3167
Oricell Presented Long-term Follow-up Data of OriCAR-017 in RRMM at 2024 ASCO Annual Meeting, Highlighting the Sustained Efficacy of GPRC5D CAR-T Therapy
SHANGHAI and ROSELAND, N.J., June 5, 2024 /PRNewswire/ -- Oricell Therapeutics, a pioneering clinical-stage biopharmaceutical company, has presented the two-year long-term follow-up results of OriCAR-017, an open-label Phase I study evaluating GPRC5D-targeted CAR-T therapy in patients with relaps...
2024-06-05 19:59
4487
FDA Approved Phase II/III Clinical Study of KPG-121 in Combination with Abiraterone as a First Line Treatment for mCRPC
HEFEI, China, June 5, 2024 /PRNewswire/ -- Kangpu Biopharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has recently approved a Phase II/III clinical trial of KPG-121 in combination with Abiraterone for a first-line treatment of metastatic castration resistant prost...
2024-06-05 19:00
2980
Week's Top Stories
Most Reposted
Carro secures strategic investment from Orico
[Picked up by 293 media titles]
2026-09-18 16:29Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
[Picked up by 289 media titles]
2026-09-15 11:00
Avnet and The University of Hong Kong Open EMUS Lab to Accelerate AI Innovation and Commercialization in Hong Kong
[Picked up by 281 media titles]
2026-09-17 13:09
Tetra Pak and Soy Excellence Center Asia Host Regional Soy Food and Beverage Programme in Thailand
[Picked up by 268 media titles]
2026-09-18 11:51
Sovereign Investment Institutions Launch China-ASEAN Joint Investment Council
[Picked up by 267 media titles]
2026-09-16 09:09
Most Read
Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
2026-09-15 11:00
9175
QIVIKA to Launch Smart Scope on Kickstarter, Bringing a Professional Long-Range Experience to Day-and-Night Exploration
2026-09-12 09:00
8317
Temporal Raises $550 Million in Series E Round: NYSE Content Update
2026-09-14 21:14
7584
